Treatment of type 2 diabetes with glucagonlike peptide 1

Current Opinion in Endocrinology and Diabetes

Volumn 5, Issue 2, 1998, Pages 108-115

  Holst, Jens Juul ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1;

DRUG EFFECT; FOOD INTAKE; GENE MUTATION; GLUCOSE INTOLERANCE; HUMAN; INSULIN LIKE ACTIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW;

EID: 0031780739     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199804000-00006     Document Type: Review

References (78)

1. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC: Exon duplication and divergence in the human preproglucagon gene. Nature 1983, 304:368-371.
2. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF: Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986, 261:11880-11889.
3. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B: Glucagon-like peptlde-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992, 22:283-291.
4. Bell GI, Santerre RF, Mullenbach GT: Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983, 302:716-718.
5. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Ørskov C: Proglucagon processing in porcine and human pancreas. J Biol Chem 1994, 269:18827-1883.
6. Ørskov C, Holst JJ, Knuhtsen S, Baldissera FGA, Poulsen SS, Nielsen OV: Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from the pig small intestine, but not pancreas. Endocrinology 1986, 119:1467-1475.
7. Holst JJ: Enteroglucagon. Annu Rev Physiol 1997, 59:257-271.
8. Drucker DJ, Ehrlich P, Asa SL, Brubaker PL: Induction of intestinal epithelial proliferation by glucagon-like peptide-2. Proc Natl Acad Sci U S A 1996, 93:7911-7916.
9. Ørskov C, Bersani M, Johnsen AH, Højrup P, Holst JJ: Complete sequences of glucagon-like peptide-1 (GLP-1) from human and pig small Intestine. J Biol Chem 1989, 264:12826-12829.
10. Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ: Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994, 43:535-539.
11. Ørskov C, Wettergren A, Holst JJ: The metabolic rate and the biological effects of GLP-1 7-36 amide and GLP-1 7-37 in healthy volunteers are identical. Diabetes 1993, 42:658-661.
12. Pridal L, Deacon CF, Kirk O, Christensen JV, Carr RD, Holst JJ: Glucagon-like peptide (7-37) has a larger volume of distribution than glucagon-like peptide-1 (7-36) amide and Is degraded more quickly by plasma in vitro in dogs. Eur J Drug Metab Pharmacokinet 1996, 21:51-59.
13. Varndell IM, Bishop A, Sikri E: Localization of glucagon-like peptide GLP immunoreactants in human gut and pancreas using light and electron microscopy. J Histochem Cytochem 1985, 33:1080-1090.
14. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V: Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993, 138:159-166.
15. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretln activity of GLP-1 (7-36 amide) but not of synthetic human GIP in patients with type 2-diabetes mellitus. J Clin Invest 1993, 91:301-307.
16. Balks HJ, Holst JJ, Hoffmann B, Von zür Mühlen A, Brabant G: Rapid oscillations in plasma GLP-1 in humans. Cholinergic control of secretion via muscarinic receptors. J Clin Endocrinol Metab 1997, 82:786-790.
17. Ørskov C, Wettergren A, Holst JJ: Secretion of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996, 31:665-670.
18. Schirra J, Katschinsky M, Weidmann C, Schafer T, Wank U, Arnold R, Göke B: Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996, 97:92-103.
19. Ørskov C, Poulsen SS: Glucagon-like peptide-1 receptors only in islets of Langerhans. Autoradiographic: survey of extracerebral tissues in rat. Diabetes 1991, 40:1292-1296.
20. Scott Heller R, Kieffer TJ, Habener JF: Insulinotropic glucagon-like peptide-1 receptor expression in glucagon-producing α-cells of the rat endocrine pancreas. Diabetes 1997, 46:785-791. A technically advanced study demonstrating beyond doubt that the glucagon-producing cells possess GLP-1 receptors.
21. Holst JJ, Ørskov AC, Schwartz TW, Nielsen OV: Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987, 211:169-174.
22. Ørekov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptlde-1 (proglucagon 78-107 amide) on endocrine secretion from pig pancreas, antrum and stomach. Endocrinology 1988, 123:2009-2013.
23. Fehmann HC, Göke R, Göke B: Cell and molecular biology of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin releasing polypeptide (GIP). Endocr Rev 1995, 16:390-410.
24. 2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 1997, 46:792-800. Another technically advanced study providing the suprising information that the effect of GLP-1 on single a cells is to stimulate glucagon secretion.
25. Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, Montrose-Rafizadeh D, Elahi D, Egan JM: Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 1997, 99:2883-2889. The results of this important study indicate that the beneficial effects of GLP-1 extend beyond merely enhancing insulin release on an acute basis.
26. Dachicourt N, Serradas P, Bailbe D, Kergoat M, Doare L, Portha B: Glucagon-like peptide 1 (7-36) amide confers glucose sensitivity to previously glucose incompetent beta cells in diabetic rats: in vivo and in vitro studies. J Endocrinol 1997, 155:369-376.
27. Gromada J, Holst JJ, Rorsman P: Cellular regulation of islet hormone secretion by the incretin hormone, glucagon-like peptide 1. Eur J Physiol 1998, 435:583-584.
28. Thorens B, Porrel A, Bühler L, Deng S-H, Morel P, Widmann C: Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin 4 is an agonist and exendin 9-39 an antagonist of the receptor. Diabetes 1993, 42:1678-1682.
29. Holz GG, Kühltreiber WM, Habener JF: Pancreatic beta-cells are rendered glucose competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature 1993, 361:362-365.
30. Gromada J, Dissing S, Bokvist K, Renström E, FrØkjaer-Jensen J, Wulff BS, Rorsman P: Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting βTC3-cells by enhancement of intracellular calcium mobilization. Diabetes 1995, 44:767-774.
31. Hvidberg A, Toft Nielsen M, Hilsted J, Ørskov C, Holst JJ: Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 1994, 43:104-108.
32. Morales M, Lopez-Delgado MI, Alcantarra A, Luque MA, Clemente F, Marquez L, Puente J, Vinambres C, Malaisse WJ, Villanueva-Penacarillo ML, Valverde I: Preserved GLP-1 effects on glycogen synthese A activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 1997, 46:1264-1269. This is one of the latest of a long series of studies from the Madrid group, which all indicate that GLP-1 may have direct effects on glucose uptake and handling by muscle and adipose tissues. As discussed previously, this is a controversial issue but may reflect differences between species because similar effects are not easily detected in human subjects.
33. Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, Adams LG: Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol 1997, 172:275-283.
34. Toft-Nielsen M, Madsbad S, Holst JJ: The effect of GLP-1 on glucose elimination. Diabetes 1996, 45:552-556.
35. Ørskov L, Holst JJ, Ørskov C, Møller N, Alberti KGMM, Schmitz O: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 1995, 39:1227-1232.
36. Larsson H, Holst JJ, Ahrén B: Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997, 160:413-422.
37. Ahren B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997, 82:473-478.
38. Creutzfeldt W, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide-1 (7-36 amide) in type I diabetic patients. Diabetes Care 1996, 19:580-586. This study shows that GLP-1 lowers blood glucose levels even in type 1 diabetic patients with no β-cell secretory capacity left and therefore illustrates the importance of the glucagonostatic actions of GLP-1.
39. Kolligs F, Fehmann HC, Göke R, Göke B: Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin (9-39) amide. Diabetes 1995, 44:16-19.
40. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei M, Bloom SR: Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 1995, 95:417-421.
41. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996, 2:1254-1258. In this paper the consequences of a life without GLP-1 functions are demonstrated: without this important incretin hormone diabetes ensues.
42. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 72-107 amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993, 38:665-673.
43. Layer P, Holst JJ, Grandt D, Goebell H: Ileal release of glucagonlike peptide-1 (GLP-1): association with inhibition of gastric acid in humans. Dig Dis Sci 1995, 40:1074-1082.
44. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzelt R, Schmiegel WH: The glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997, 273:2295-2302. This study clearly illustrates the potent effects of GLP-1 on gastric emptying.
45. Wettergren A, Wejdemann M, Meisner S, Stadil F, Holst JJ: The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997, 40:597-601.
46. Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh SP, Holst JJ: Glucagon-like peptide-1 (GLP-1) 7-36 amide and peptide YY from the L-cell in the ileal mucosa are potent inhibitors of vagally induced gastric acid in man. Scand J Gastroenterol 1994, 29:501-505.
47. Ørskov C, Poulsen SS, Møller M, Holst JJ: GLP-1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide-1. Diabetes 1996, 45:832-835.
48. Imeryuz N, Yegen BC, Bozkurt A, Vcoskun T, Villanueva-Penacarillo ML, Ulusoy NB: Glucagon-like peptide 1 inhibits gastric emptying via vagal afferent mediated central mechanisms. Am J Physiol 1997, 36:G920-G927.
49. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A: Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 1996, 271:E808-E813.
50. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101:515-520.
51. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, et al.: A role for glucagon-like peptide-1 in the regulation of feeding. Nature 1996, 379:69-72.
52. Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, Sheikh SP: Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996, 271:R848-R856. A very careful study documenting the inhibitory effects of ICV GLP-1 on food intake.
53. Thiele TE, Van Dijk G, Campfield LA, Smith FJ, Burn P, Woods SC, Berstein IL, Seeley RJ: Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol 1977, 272:R726-R730.
54. Bloom SR: Glucagon-like peptide-1 and satiety: reply [letter]. Nature 1997, 385:214.
55. Göke R, Larsen PJ, Mikkelsen JD, Sheikh S: Distribution of GLP-1 binding sites in the rat brain. Evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995, 7:2294-2300.
56. Larsen PJ, Tang-Christensen M, Jessop DS: Central administration of glucagon-like peptide-1 activates neuroendocrine neurons in the rat. Endocrinology 1997, 138:4445-4455. A careful study demonstrating a probable pathway for the actions of cerebral GLP-1.
57. McMahon LR, Wellman PJ: Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7-36) amide. Pharmacol Biochem Behav 1997, 58:673-677.
58. Larsen PJ, Tang-Christensen M, Holst JJ, Ørskov C: Distribution of glucagon-like peptide-1 (GLP-1) and other preproglucagon derived peptides in the rat hypothalamus and brain stem. Neuroscience 1997, 77:257-270. This study maps the occurrence of GLP-1-producing neurons in the brain and traces their nerve fibers to the hypothalamus.
59. Gutniak M, Ørskov C, Holst JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992, 326:1316-1322.
60. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36 amide) in type 2-diabetic patients. Diabetologia 1993, 36:741-744.
61. Rachman J, Barrow BA, Levy JC, Turner RC: Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997, 40:205-211. This study shows that GLP-1 effectively lowers blood glucose level in type 2 diabetic patients, not only in the fasting state but also in connection with food intake.
62. Larsen J, Jallad N, Darnsbo P: One-week continuous infusion of GLP-111-1(7-37) improves glycemic control in NIDDM [abstract]. Diabetes 1996, 45(suppl 2):233A. Unfortunately, this important study has not been published in full. It demonstrates the viability of the hypothesis that activation of GLP-1 receptors is an eminent treatment for type 2 diabetes. Surprisingly good diabetic control was obtained throughout 7 days of continuous intravenous GLP-1 infusion with no signs of tachyphylaxis or untoward side effects.
63. Nauck MA, Holst JJ, Willms B: Glucagon-like peptide-1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 1997, 29:411-416.
64. Ritzel R, Ørskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 1995, 38:720-725.
65. Nauck MA, Wollschlager D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide-1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996, 39:1546-1553.
66. Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Efendic S: The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 1996, 19:1200-1206.
67. Todd JF, Wilding JP, Edwards CM, Khan FA, Ghatei MA, Bloom SR: Glucagon-like peptlde-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997, 27:533-536.
68. Deacon CF, Pridal CF, Klarskov L, Olesen M, Holst JJ: Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996, 271:E458-E464. This study demonstrates the dramatically rapid and extensive metabolizating of GLP-1, a major obstacle in the therapeutic use of the peptide.
69. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptlde-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952-957.
70. Knudsen LB, Pridal L: Glucagon-like peptide-1 (9-36) amide is a major metabolite of glucagon-like peptide-1 (7-36) amide after in vivo administration to dogs, and acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996, 318:429-435.
71. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ: Both subcutaneous and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44:1126-1131.
72. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ: Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998, 41:271-278.
73. Pridal L, Agerbæk H, Christensen LN, Thomsen K, Kirk O: Absorption of glucagon-like peptide-1 can be protracted by zinc or protamine. Int J Pharm 1996, 136:53-59.
74. Deacon CF, Hughes TE, Hoist JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anaesthetized pig. Diabetes 1998, in press.
75. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B: Potentially therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care 1996, 19:843-848.
76. Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B: GLP-1 tablet in NIDDM in fasting and postprandial conditions. Diabetes Care 1997, 20:1874-1879.
77. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W: Glucagon-like peptide-1 (GLP-1) [7-36 amide] secretion in response to luminal sucrose from the upper and lower gut A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995, 30:892-896
78. Seifarth C, Bergmann J, Holst JJ, Ritzelt R, Schmiegel W, Nauck MA: Influence of acarbose on GLP-1 release after a sucrose load in NIDDM patients [abstract]. Diabetologia 1997, 40(suppl 1):A131.